biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce the appointment of Mr. John McKay as a member of the Company’s Advisory Board. “John has vast expertise in the Pharmaceutical and Biotech fields” says Rob Hutchison, CEO “his industry knowledge and contacts gained through 20 years with SmithKline Beecham and 10 years with Warner Lambert / Parker David and in his current consultancy position, are extremely valuable to biOasis, particularly as we try to identify partners for our technology.”
Since late 2000, John established JHM PharmaServices to provide consultancy services in Marketing Strategy, Business Development, Product Assessment and Licensing to various large Pharmaceutical and Bio-Pharmaceutical clients.
Prior to that John was 20 years with SmithKline Beecham, most latterly as Vice President and Director Global Marketing (formerly Strategic Product Development). In this role he was responsible for the worldwide commercial development of major products and the new product pipeline.
During his career he has held General Management and Marketing Management positions in Canada, Brazil, Italy, Latin America and China for SmithKline Beecham and for Warner Lambert. Prior to entering the pharmaceutical industry he had experience in science and new product development positions in the animal agriculture industry.
He holds Science and Business degrees from Mount Allison University and Queens University in Canada.
About biOasis
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It obtained extensive and
|
|
comprehensive intellectual property (the “IP”) from the University of British Columbia. The Company's initial area of focus will be to utilization of its IP to pursue a biomarker for the diagnosis of Alzheimer's disease.
The Alzheimer's Association reports that a n estimated 24 million+ people currently live with dementia worldwide, and this figure is projected to increase to 81 million by 2040 .
According to the report, "An Estimate of the Total Worldwide Societal Costs of Dementia in 2005" by the Alzheimer's Association, the total worldwide cost of dementia care was estimated to be US$315.4 billion annually. The world's most developed regions, mainly North America and Europe, account for 77% of the worldwide cost. In terms of individual countries, the total cost was highest in the U.S. at US$76 billion, followed by Japan at US$34 billion and China at US$28 billion.
Alzheimer's disease accounts for more than 50% of cases of dementia in Caucasian populations; however, this may not apply to other national or ethnic groups. The costs associated with Alzheimer's will rise as the population is aging in the developed countries. With a better diagnostic tool, the future for Alzheimer's patients is encouraging. Earlier diagnosis will enable earlier (and more effective) treatment and as a companion to new therapeutics will improve the lives of many people.
To find out more about biOasis Technologies Inc. visit .
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”
On Behalf of the Board of Directors
“ Robin Hutchison ”
Robin Hutchison, Chairman and CEO
|
